PDF
ePub
Citation
Print
Abstract
Uterine myomas are the most common benign pelvic tumors in reproductive aged women occurring in 25~40%. They may cause menstrual dysfunction, pressure symptoms and pain, subfertility, recurrent abortion and pregnancy-related problems. Treatment choices are variable and include observation, surgery, medication, myolysis, and uterine artery embolization. Most myomas are asymptomatic and can be followed serially with surveillance of growth and symptom development. For the choice of therapeutic modality the clinicians should understand many factors including age, parity, fertility preservation, extent and severity of symptoms, size and number of myomas, location, associated medical problems, possibility of malignancy, proximity to menopause and desire for uteine preservation. It is important to make an indivisualized treatment plan flexibly after considering and discussing risk/ benefit ratios and clinical situations.
References
1. Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology symptomatology and management. Fertil Steril. 1981. 36:433.
2. Hacker NF, Moore JG. Essentials of obstetrics and gynecology. 1998. 3rd ed. Philadelphia: WB Saunders;413.
3. Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update. 1996. 2:295–306.
4. Seoud MA, Patterson R, Muasher SJ, Doddington CC. Effects of myomas or prior myomectomy on in vitro fertilization(IVF) performance. J Assist Reprod Genet. 1992. 9:217–221.
5. Propst AM, Hill JA 3rd. Anatomic factors associated with recurrent pregnancy loss. Semin Reprod Med. 2000. 18:341–350.
6. Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol. 1989. 109:1–6.
7. Philip NR, Urvashi S. Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells. Am J Obstet Gynecol. 1995. 173:571–577.
8. Dou Q, Zhao Y, Tamuzzer RW, Rong H, Williams RS, Shultz GS, et al. Suppression of transforming growth factor-beta and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin releasing hormone agonist therapy. J Clin Endocrinol Metab. 1996. 81:3222–3230.
9. Schoenberg FM, Ashar HR, Krauter KS, Powell WL, Rein MS, Weremovicz S, et al. Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas. Genes Chromosomes Cancer. 1996. 17:1–6.
10. Williams AJ, Powell WL, Collins T, Morton CC. HMGI(Y) expression in human uterine leiomyomata. Involvement of another high-mobility group architectural factor in a benign neoplasm. Am J Pathol. 1997. 150:911–918.
11. Edward EW, Nikos FV. Uterine myomas : An overview of development, clinical features, and management. Obstet Gynecol. 2004. 104:393–406.
12. Kjerulff KH, Langenberg PW, Rhodes JC, Harvey LA, Guzinski GM, Stolley PD. Effectiveness of hysterectomy. Obstet Gynecol. 2000. 95:319–326.
13. Harkki-Siren P, Sjoberg J, Tiitinen A. Urinary tract injuries after hysterectomy. Obstet Gynecol. 1998. 92:113–118.
14. Oliveira FG, Abdelmassih VG, Diamond MP, Dozortsev D, Melo NR, Abdelmassih R. Impact of subserosal and intramural uterine fibroids that do not distort the endometrial cavity on the outcome of in vitro fertilization-intracytoplasmic sperm injection. Fertil Steril. 2004. 81:582–587.
15. Rossetti A, Sizzi O, Soranna L, Cucinelli F, Mancuso S, Lanzone A. Long-term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy. Human Reproduction. 2001. 16:770–774.
16. Cohen LS, Valle RF. Role of vaginal sonography and hysterosonography in the endoscopic treatment of uterine myomas. Fertil Steril. 2000. 73:197–294.
17. Tiltman AJ. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol. 1985. 4:89–96.
18. Golan A. GnRH analogues in the treatment of uterine fibroids. Hum Reprod. 1996. 11:Suppl 3. 33–41.
19. Donnez J, Schrurs B, Gillerot S, Sandow J, Clerckx F. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril. 1989. 51:947–950.
20. Nisolle M, Smerts M, Malvaux V, Anaf V, Donnez J. Laparoscopic myolysis with the Nd:YAG laser. J Gynecol Surg. 1993. 9:95–99.
21. Donnez J, Squifflet J, Polet R, Nisolle M. Laparoscopic myolysis. Hum Reprod Update. 2000. 6:609–613.
22. Bergamini V, Ghezzi F, Cromi A, Bellini G, Zanconato G, Scarperi S, et al. Laparoscopic radiofrequency thermal ablation: A new approach to symptomatic uterine myomas. Am J Obstet Gynecol. 2005. 192:768–773.
23. Heaston DK, Mineau DE, Brown BJ, Miller FJ Jr. Transcatheter arterial embolization for control of persistent massive puerperal hemorrhage after bilateral surgical hypogastric artery ligation. Am J Roentgenol. 1979. 133:152–154.
24. Ravina JH, Herbreteau D, Ciraru-Vigneron N, Bouret JM, Houdart E, Aymard A. Arterial embolization to treat uterine myoma. Lancet. 1995. 346:671–672.
25. Goodwin SC, Walker WJ. Uterine artery embolization for the treatment of uterine fibroids. Current Opin Obstet Gynecol. 1998. 10:315–320.
26. Hovsepian DM, Siskin GP, Bonn J. Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata, standards of practice. J Vasc Interv Radiol. 2004. 15:535–541.
27. Goldberg J, Pereira L, Berghella V. Pregnancy after uterine artery embolization. Obstet Gynecol. 2002. 100:869–872.
28. American college of obstetricians and gynecologists. ACOG committee opinion, Uterine artery embolization. Obstet Gynecol. 2004. 293:403–404.
XML Download